CompletedNCT00094432
A Study of Aripiprazole in Patients With Bipolarity type I With a Major Depressive Episode
Medication studyAges 18–65United States
Understand this study
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Mesa and 39 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 650
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00094432
- Official title
Show the full official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST.
Recruitment & locations
CompletedMesa · La Mesa · La Palma
37 more locations
- Long Beach
- Redlands
- San Diego
- Sherman Oaks
- Washington D.C.
- Coral Springs
- Jacksonville
- St. Petersburg
- Marietta
- Edwardsville
- Oak Brook
- Springfield
- Lafayette
- Newton
- New Orleans
- Shreveport
- Baltimore
- St Louis
- Clementon
- Albuquerque
- Brooklyn
- Elmsford
- New York
- Raleigh
- Dayton
- Media
- Philadelphia
- Pittsburgh
- Columbia
- DeSoto
- Houston
- Wichita Falls
- Salt Lake City
- Charlottesville
- Midlothian
- Bellevue
- Charleston
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole and Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me